Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
• Informed and written signed consent
• Participant with regular health insurance
Locations
Other Locations
France
Hôpital de la Croix Rousse - SMIT
RECRUITING
Lyon
Hôpital Saint-Louis - SMIT
RECRUITING
Paris
Hôpital Tenon - SMIT
RECRUITING
Paris
Contact Information
Primary
Fatoumata Coulibaly
fatoumata.coulibay@inserm.fr
0144236110
Backup
Mathilde Ghislain, MSc
mathilde.ghislain@inserm.fr
0145595229
Time Frame
Start Date: 2025-03-20
Estimated Completion Date: 2027-07-30
Participants
Target number of participants: 100
Treatments
Other: High-resolution anoscopy
Related Therapeutic Areas
Sponsors
Leads: ANRS, Emerging Infectious Diseases
Collaborators: INSERM SC10-US19